Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AstraZeneca's Breztri (budesonide/glycopyrrolate/formoterol fumarate) gains FDA approval for asthma in patients aged 12 and older following Ph3 success
Small molecule, respiratory disease, inhaled corticosteroid, asthma, COPD, fixed-dose combination - Read more

Remepy, Merck KGaA collaborate on app-paired hybrid drug model for rare tumour treatments
Research collaboration, oncology, rare disease, digital health, AI/ML - Read more

Eli Lilly, Profluent Bio partner on AI-designed DNA editing tools for genetic medicines, up to $2.25B milestones
Research collaboration, rare disease, gene therapy, AI/ML, milestone payments, royalties - Read more

Protagonist Therapeutics opts out of US rusfertide profit split, securing $475M from Takeda
Licensing deal, rare disease, small molecule, milestone payments, royalties - Read more

Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180M
Rare disease, gene therapy, priority review voucher, hematopoietic stem cell, cardiovascular - Read more

BeOne Medicines, Huahui Health partner on trispecific antibody HH160, $20M upfront, $1.87B milestones
Licensing deal, oncology, antibody, milestone payments, equity investment - Read more

🚨 Applications are open for the 2026 Lilly Grand Challenge: Aging Reimagined

🔬 $100K in non-dilutive funding (no strings attached)
🏛️ A 2 day pitch at Lilly HQ in Indianapolis (all expenses paid)
🤝 Direct access to Lilly's scientific and venture teams

This year’s focus: Aging Reimagined — New Health Frontiers (mobility, cognition, immune resilience, regenerative medicine).

If you’re building in this space - or know someone who is - don’t miss this!

📅 Deadline: May 15

👉 Learn More and Apply Here: https://linktr.ee/lillygrandchallenge

Asgard Therapeutics presents preclinical data on AT-108 cancer immunotherapy ahead of clinical advancement
Gene therapy, cancer, in vivo cell reprogramming, tumor microenvironment, cancer immunotherapy, antigen-presenting cells - Read more

Boehringer Ingelheim's (survodutide) meets Ph3 goals in obesity, showing significant weight loss with muscle preservation
Protein therapy, metabolic, GLP-1 agonist, obesity, MASH, glucagon receptor agonist - Read more

Erasca's (ERAS-0015) Ph1 pan-RAS molecular glue shows 40–62% response rates in RAS-mutant solid tumors
Small molecule, cancer, molecular glue, pancreatic cancer, non-small cell lung cancer, RAS mutation - Read more

Incyte plans vitiligo submission for (povorcitinib) following Ph3 STOP-V1 and STOP-V2 trial success
Small molecule, autoimmune, JAK1 inhibitor, vitiligo, hidradenitis suppurativa - Read more

Novartis reaffirms $5B Pluvicto peak sales goal despite European label withdrawal and competitive pressures
Radioligand therapy, oncology, regulatory, financial, competitive - Read more

Coultreon Biopharma raises $125M Series A to advance oral SIK3 autoimmune drug
Autoimmune, small molecule, oral drug, clinical-stage, SIK inhibitor - Read more

Northern Gritstone closes £20M ($27M) additional share commitments, totaling £382M permanent capital
Venture capital, life sciences, deeptech, AI, gene therapy - Read more

Lighthouse Pharmaceuticals closes $12M Series A to advance Alzheimer's disease program LHP588
Clinical-stage, small molecule, Alzheimer disease, neurological, neurodegenerative - Read more

CTIBIOTECH receives €1.25M ($1.47M) from Bpifrance to launch CTIONCOTEST 3D bioprinting platform
Oncology, 3D bioprinting, drug discovery, tissue engineering, cancer, preclinical - Read more

AbbVie gains exclusive right to acquire Kestrel Therapeutics for up to $1.45B, targeting oral pan-KRAS inhibitor
Acquisition option, oncology, small molecule, milestone payments - Read more

FDA launches real-time clinical trial data review initiative with AstraZeneca and Amgen in pilot program
Regulatory innovation, operational, strategic, competitive - Read more

Orca Bio's Orca-Q receives FDA RMAT designation for high-risk hematologic malignancies treatment
Allogeneic T-cell therapy, hematologic malignancies, regulatory, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Janux Therapeutics halts JANX008 (masked EGFR/CD3 T-cell engager) Ph1 development in metastatic solid tumors due to insufficient activity
Antibody, cancer, bispecific T-cell engager, solid tumor, EGFR, CD3 - Read more

Novartis Q1 sales dip 5% as generic erosion hits Entresto, radioequivalent competition looms for Lutathera
Radioligand therapy, oncology, financial, competitive, revenue impact - Read more

GSK's Tesaro loses pre-trial ruling in Jemperli royalty dispute with AnaptysBio
Monoclonal antibody, oncology, competitive, financial - Read more

Revolution Medicines threatens legal action against Erasca over pancreatic cancer drug patent infringement claims
Small molecule, oncology, competitive, financial - Read more

Novartis CEO calls for "complete rethink" of Europe's drug pricing policies, warning of delayed medicine access
Drug pricing, regulatory, strategic, competitive, revenue impact - Read more

FDA raises trial design and efficacy concerns for AstraZeneca's camizestrant and Truqap ahead of advisory meeting
Small molecule, oncology, regulatory, competitive - Read more

FDA alleges Amgen's Tavneos approval was backed by manipulated clinical trial data, calls for withdrawal
Small molecule, autoimmune, regulatory, rare disease - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here